Viridian Therapeutics announced positive results from a second Phase 3 trial of its drug for thyroid eye disease, a condition causing bulging eyes and vision problems. The therapy, which targets a protein linked to inflammation, met its primary endpoint of improving proptosis, or eye bulging, compared to placebo. This follows a prior successful Phase 3 readout, positioning the company for a potential regulatory filing.
The win strengthens Viridian's hand against competitors like Amgen, which markets Tepezza, the only FDA-approved treatment for the disease. If approved, Viridian's drug could offer a less invasive alternative, as it is administered via subcutaneous injection versus intravenous infusion. The biotech sector has closely watched these results, given the multi-billion-dollar market opportunity in thyroid eye disease therapy.
Elsewhere, Takeda reported a Phase 2/3 win for a gene therapy targeting a rare metabolic disorder, though specific efficacy data was not disclosed. The trial enrolled pediatric patients with a severe enzyme deficiency, and the therapy aims to correct the underlying genetic defect. Takeda plans to discuss the results with regulators for a potential accelerated approval path.
A UK-based cancer biotech raised $83 million in Series B funding to advance its pipeline of immunotherapies. The company focuses on developing bispecific antibodies that engage the immune system against solid tumors. Proceeds will fund two Phase 1 trials and expand manufacturing capabilities, according to the firm.
Viridian's success is not guaranteed approval; prior Phase 3 wins have occasionally failed to replicate in larger studies or faced manufacturing hurdles. Additionally, Takeda's gene therapy requires long-term safety monitoring, a common challenge for the modality. The UK biotech's early-stage assets remain high-risk despite the substantial financing.